All In Biotech

Drug Trial Radar · NCT04655911

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

A Long-term Follow-up Study of Patients With MPS IIIB From Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU)

Last checked: Nov 19, 2026Latest source record: May 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Oct 28, 2020

Primary completion

Apr 7, 2022

Study completion Apr 7, 2022

Sponsor

Lead sponsor
Abeona Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Dec 7, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, non-interventional, long-term follow-up (LTFU) study in participants who have been treated with ABO-101 in a prior trial. Eligible participants will undergo clinical evaluations at prespecified intervals for 3 years from the last visit in the prior clinical trial (up to 5 years post-treatment).

Conditions

  • Mucopolysaccharidosis III-B

Interventions

  • ABO-101Biological

    Gene therapy rAAV9.CMV.hNAGLU

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 60 months

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Armand-Trousseau Hospital

    Paris, France

  • University Hospital Hamburg-Eppendorf

    Hamburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.